Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 571

9.

Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.

Abelson MB, Torkildsen GL, Williams JI, Gow JA, Gomes PJ, McNamara TR; Bepotastine Besilate Ophthalmic Solutions Clinical Study Group.

Clin Ther. 2009 Sep;31(9):1908-21. doi: 10.1016/j.clinthera.2009.09.001.

PMID:
19843481
10.

Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge.

Mah FS, Rosenwasser LJ, Townsend WD, Greiner JV, Bensch G.

Curr Med Res Opin. 2007 Jun;23(6):1445-52. Epub 2007 May 18.

PMID:
17559743
11.

Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model.

Lanier BQ, Finegold I, D'Arienzo P, Granet D, Epstein AB, Ledgerwood GL.

Curr Med Res Opin. 2004 Aug;20(8):1227-33.

PMID:
15324525
12.
13.

Efficacy and safety of single- and multiple-dose ketotifen fumarate 0.025% ophthalmic solution in a pediatric population.

Abelson MB, Ferzola NJ, McWhirter CL, Crampton HJ.

Pediatr Allergy Immunol. 2004 Dec;15(6):551-7.

PMID:
15610370
16.

Comparison of emedastine 0.05% or nedocromil sodium 2% eye drops and placebo in controlling local reactions in subjects with allergic conjunctivitis.

Orfeo V, Vardaro A, Lena P, Mensitieri I, Tracey M, De Marco R.

Eur J Ophthalmol. 2002 Jul-Aug;12(4):262-6.

PMID:
12219994
20.

Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis.

Abelson MB, Gomes P, Crampton HJ, Schiffman RM, Bradford RR, Whitcup SM.

Clin Ther. 2004 Jan;26(1):35-47.

PMID:
14996516

Supplemental Content

Support Center